Biotage to Unveil New Advanced Sample Preparation Products at PITTCON 2008
Biotage, the leading supplier of tools and technology for medical and analytical chemistry, announces the launch of the latest addition to its EVOLUTE® family of sample preparation products. The EVOLUTE ABN 50 µm range has been specifically designed for use in environmental, forensic and industrial applications and provides a highly effective solution to the challenges of ion suppression and matrix effects from dirty extracts. The EVOLUTE ABN 50 µm product series will be showcased exclusively on booth #2934 at PITTCON 2008, from 1-7 March 2008.
Biotage’s new EVOLUTE ABN 50 µm range is ideally suited for trace enrichment analysis of environmental contaminants in large-volume aqueous samples. With a unique modified and water-wettable surface structure, EVOLUTE ABN promotes robust and reliable sample preparation. A balanced combination of polar and non-polar interactions enables efficient extraction of analytes of wide-ranging polarity. Additionally, EVOLUTE ABN columns can be used in a variety of application areas including food, agrochemical and industrial analysis.
Also on view at PITTCON will be the ISOLUTE® SLE+ Supported Liquid Extraction Product, providing an easier-to-automate alternative to traditional liquid-liquid extraction (LLE), eliminating all off-line steps and cutting sample preparation time in half. Problems such as emulsion formulation and automated pipetting of liquid layers are also avoided as the two phases do not come into direct contact. The ISOLUTE SLE+ mechanism is extremely robust and can deliver higher analyte recoveries and cleaner extracts than the equivalent LLE methods.
Jennifer Whedbee, Director Marketing Communications at Biotage, said: “Our new EVOLUTE and ISOLUTE products minimize sample preparation problems providing clean sample extracts while minimizing method development time and improving productivity. We are excited to showcase the benefits of these new expanded product lines for the first time at PITTCON 2008.”
The Biotage V-10 Solvent Evaporator with new carousel and enhanced software will also be demonstrated at PITTCON 2008. This revolutionary new system incorporates patented three-way drying technology which improves evaporation speed of both aqueous and organic solvents up to 20 times faster than conventional rotary and centrifugal systems. Using a patented combination of high-speed vial rotation, uniform warm-air heating and vacuum drying, this unique system provides rapid evaporation of solvents with boiling points ranging from 30 to 206ºC.
For more information on the EVOLUTE ABN 50 µm, ISOLUTE SLE+ or the V-10 Solvent Evaporator, please visit booth #2934. Alternatively please call 434-979-2319 (press 3), email firstname.lastname@example.org, or visit www.biotage.com
Torben Jörgensen, President and CEO
Tel: +46 1856 59 00, email@example.com
Jennifer Whedbee, Director Marketing Communications
Tel: +1 434 220 2652, firstname.lastname@example.org
For further press information please contact: Eleanor CallanMonk, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: email@example.com
Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. In 2005 operations and products were acquired from the American company Argonaut, further strengthening the medicinal chemistry product range. The customers include the worlds top 30 pharmaceutical companies, the worlds top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several other European countries. Biotage has 332 employees and had sales of 520 MSEK in 2006. Biotage is listed on the OMX Nordic Exchange Stockholm AB. Website: www.biotage.com
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as \"believe,\" \"expect,\" \"intend,\" and \"should,\" among others. These forward-looking statements are based on Biotage’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a \"safe harbor\" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotage’s products (including seasonal fluctuations), difficulties in successfully adapting the Company’s products to integrated solutions and producing such products, and the Company’s ability to identify and develop new products and to differentiate its products from competitors.
The following files are available for download:
TurboVap® in German
Biotage Acquires Horizon Technology
Extraction of Acidic Catecholamine Metabolites in Plasma Using ISOLUTE® SLE+ Prior to LC-MS/MS Analysis
Video Demonstration: Multi Racks for TurboVap®
Effective Purification of Peptides using Normal Phase Flash